Skip to main content
SNGX logo

SNGX

Soligenix, Inc.
$0.39 +0.01 (+2.63%) At close · Jul 7
Market Cap
$5.72M
Shares
14,824,174

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.39 Open$0.38 Day$0.38–0.39 52W$0.28–6.23 Avg vol 30d14.2M Short int479K · 3.2% float · 1.0d Short vol13% DataJan 2020–Jul 2026 Filing10-Q · May 8
Equibles Rating blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −66%
below
Price vs 50-day avg −19%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −11%
trailing
6-month return −72%
trailing
YTD return −71%
this year
Relative strength −79%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-21% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.23% of float · ▼ -92.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 2-yr range
Squeeze score 30
low risk · 0–100
Fundamentals
Strong
Revenue growth −86%
Y/Y
Gross margin 82%
expanding
EPS growth +57%
Y/Y
Free cash flow $-10.3M
Balance sheet $26.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 214%
annualized · 1-yr
Max drawdown −94%
past year
ATR 11.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 8, 2026

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−66% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-21% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.23% of float · ▼ -92.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $0 Now $0 · 2% 52-wk high $6
vs 200-day avg -66% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SNGX
Soligenix, Inc.
this stock
$5.72M -70.9% -85.8% 3.2%
ONC
BeOne Medicines Ltd.
$436.30B -0.6% +22179.2% 908.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$126.50B +9.9% +46.2% 29.6 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$69.50B -14.0% +20.8% 16.2 3.2%
ARGX
Argenx SE
$57.20B +8.8% 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
15
% held
1.8%
Net QoQ
-187.4K sh
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
479.1K
Days to cover
1.0d
Change
-6.0M sh
View
Short Volume
Short vol %
13%
As of
Jul 8, 2026
Short Total
View
Fails to Deliver
FTD shares
32
Value
$14
As of
Jun 12, 2026
View
Off-Exchange
Off-exchange %
58.6%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$119.4K
Net income (FY)
$-11.1M
EPS diluted
$-2.14
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 26, 2026
This year
8
View

Performance

5D 20D 120D MTD YTD
SNGX -2.5% -11.4% -71.5% -2.5% -70.9%
SPY +0.9% +1.4% +7.6% +0.1% +9.7%
vs SPY -3.4% -12.7% -79.1% -2.6% -80.6%
Key facts CIK 812796 CUSIP 834223604 13F (30d) 1 filings 1 filers Visit website Investor relations